Eicosanoid lipid mediators in fibrotic lung diseases: Ready for prime time?

Chest

Volumn 133, Issue 6, 2008, Pages 1442-1450

  Huang, Steven K ^a   Peters Golden, Marc ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b Division of Pulmonary and Critical Care Medicine   (United States)

Author keywords

Airway remodeling; Leukotrienes; Prostaglandins; Pulmonary fibrosis

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOXIDANT; BLEOMYCIN; CHEMOKINE; CORTICOSTEROID; CYTOKINE; GLUTATHIONE; ICOSANOID; ILOPROST; LEUKOTRIENE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXYGENASE INHIBITOR; LOSARTAN; MONTELUKAST; PHOSPHODIESTERASE INHIBITOR; PROSTACYCLIN DERIVATIVE; PROSTAGLANDIN; PROSTAGLANDIN E2; ZILEUTON;

ARTICLE; ASTHMA; CELL TYPE; DISEASE COURSE; DRUG EFFECT; DRUG TARGETING; FIBROGENESIS; HUMAN; INFLAMMATION; LIPID METABOLISM; LUNG BLOOD VESSEL; LUNG DISEASE; LUNG FIBROSIS; LUNG PARENCHYMA; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PULMONARY HYPERTENSION;

EID: 46149094641     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.08-0306     Document Type: Article

References (56)

1. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001; 134:136-151
2. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias: this joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002; 165:277-304
3. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001; 294:1871-1875
4. Charbeneau RP, Peters-Golden M. Eicosanoids: mediators and therapeutic targets in fibrotic lung disease. Clin Sci (Lond) 2005; 108:479-491
5. Peters-Golden M, Henderson WR Jr. Leukotrienes. N Engl J Med 2007; 357:1841-1854
6. Bosse Y, Thompson C, McMahon S, et al. Leukotriene D4-induced, epithelial cell-derived transforming growth factor β1 in human bronchial smooth muscle cell proliferation. Clin Exp Allergy 2008; 38:113-121
7. Uzonyi B, Lotzer K, Jahn S, et al. Cysteinyl leukotriene 2 receptor and protease-activated receptor 1 activate strongly correlated early genes in human endothelial cells. Proc Natl Acad Sci U S A 2006; 103:6326-6331
8. Phan SH, McGarry BM, Loeffler KM, et al. Leukotriene C4 binds to rat lung fibroblasts and stimulates collagen synthesis. Adv Prostaglandin Thromboxane Res 1987; 17B:997-999
9. Vannella KM, McMillan TR, Charbeneau RP, et al. Cysteinyl leukotrienes are autocrine and paracrine regulators of fibrocyte function. J Immunol 2007; 179:7883-7890
10. Armstrong RA. Investigation of the inhibitory effects of PGE2 and selective EP agonists on chemotaxis of human neutrophils. Br J Pharmacol 1995; 116:2903-2908
11. Savla U, Appel HJ, Sporn PH, et al. Prostaglandin E(2) regulates wound closure in airway epithelium. Am J Physiol Lung Cell Mol Physiol 2001; 280:L421-L431
12. Fine A, Poliks CF, Donahue LP, et al. The differential effect of prostaglandin E2 on transforming growth factor-β and insulin-induced collagen formation in lung fibroblasts. J Biol Chem 1989; 264:16988-16991
13. White ES, Atrasz RG, Dickie EG, et al. Prostaglandin E(2) inhibits fibroblast migration by E-prostanoid 2 receptor-mediated increase in PTEN activity. Am J Respir Cell Mol Biol 2005; 32:135-141
14. Baum BJ, Moss J, Breul SD, et al. Effect of cyclic AMP on the intracellular degradation of newly synthesized collagen. J Biol Chem 1980; 255:2843-2847
15. Choung J, Taylor L, Thomas K, et al. Role of EP2 receptors and cAMP in prostaglandin E2 regulated expression of type I collagen alphal, lysyl oxidase, and cyclooxygenase-1 genes in human embryo lung fibroblasts. J Cell Biochem 1998; 71: 254-263
16. Skold CM, Liu XD, Zhu YK, et al. Glucocorticoids augment fibroblast-mediated contraction of collagen gels by inhibition of endogenous PGE production. Proc Assoc Am Physicians 1999; 111:249-258
17. Thomas PE, Peters-Golden M, White ES, et al. PGE(2) inhibition of TGF-betal-induced myofibroblast differentiation is Smad-independent but involves cell shape and adhesion-dependent signaling. Am J Physiol Lung Cell Mol Physiol 2007; 293:L417-L428
18. Zhang A, Wang MH, Dong Z, et al. Prostaglandin E2 is a potent inhibitor of epithelial-to-mesenchymal transition: interaction with hepatocyte growth factor. Am J Physiol Renal Physiol 2006; 291:F1323-F1331
19. Peters-Golden M, Bailie M, Marshall T, et al. Protection from pulmonary fibrosis in leukotriene-deficient mice. Am J Respir Crit Care Med 2002; 165:229-235
20. Beller TC, Friend DS, Maekawa A, et al. Cysteinyl leukotriene 1 receptor controls the severity of chronic pulmonary inflammation and fibrosis. Proc Natl Acad Sci U S A 2004; 101:3047-3052
21. Failla M, Genovese T, Mazzon E, et al. Pharmacological inhibition of leukotrienes in an animal model of bleomycin-induced acute lung injury. Respir Res 2006; 7:137
22. Hodges RJ, Jenkins RG, Wheeler-Jones CP, et al. Severity of lung injury in cyclooxygenase-2-deficient mice is dependent on reduced prostaglandin E(2) production. Am J Pathol 2004; 165:1663-1676
23. Moore BB, Coffey MJ, Christensen P, et al. GM-CSF regulates bleomycin-induced pulmonary fibrosis via a prostaglandin-dependent mechanism. J Immunol 2000; 165:4032-4039
24. Murakami S, Nagaya N, Itoh T, et al. Prostacyclin agonist with thromboxane synthase inhibitory activity (ONO-1301) attenuates bleomycin-induced pulmonary fibrosis in mice. Am J Physiol Lung Cell Mol Physiol 2006; 290:L59-L65
25. Borok Z, Gillissen A, Buhl R, et al. Augmentation of functional prostaglandin E levels on the respiratory epithelial surface by aerosol administration of prostaglandin E. Am Rev Respir Dis 1991; 144:1080-1084
26. Wilborn J, Crofford LJ, Burdick MD, et al. Cultured lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis have a diminished capacity to synthesize prostaglandin E2 and to express cyclooxygenase-2. J Clin Invest 1995; 95:1861-1868
27. Vancheri C, Sortino MA, Tomaselli V, et al. Different expression of TNF-alpha receptors and prostaglandin E(2) production in normal and fibrotic lung fibroblasts: potential implications for the evolution of the inflammatory process. Am J Respir Cell Mol Biol 2000; 22:628-634
28. Keerthisingam CB, Jenkins RG, Harrison NK, et al. Cyclooxygenase-2 deficiency results in a loss of the antiproliferative response to transforming growth factor-β in human fibrotic lung fibroblasts and promotes bleomycin-induced pulmonary fibrosis in mice. Am J Pathol 2001; 158:1411-1422
29. Wardlaw AJ, Hay H, Cromwell O, et al. Leukotrienes, LTC4 and LTB4, in bronchoalveolar lavage in bronchial asthma and other respiratory diseases. J Allergy Clin Immunol 1989; 84:19-26
30. Wilborn J, Bailie M, Coffey M, et al. Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary fibrosis. J Clin Invest 1996; 97:1827-1836
31. Moore BB, Peters-Golden M, Christensen PJ, et al. Alveolar epithelial cell inhibition of fibroblast proliferation is regulated by MCP-1/CCR2 and mediated by PGE2. Am J Physiol Lung Cell Mol Physiol 2003; 284:L342-L349
32. Charbeneau RP, Christensen PJ, Chrisman CJ, et al. Impaired synthesis of prostaglandin E2 by lung fibroblasts and alveolar epithelial cells from GM-CSF-/- mice: implications for fibroproliferation. Am J Physiol Lung Cell Mol Physiol 2003; 284:L1103-L1111
33. Marchand-Adam S, Marchal J, Cohen M, et al. Defect of hepatocyte growth factor secretion by fibroblasts in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003; 168: 1156-1161
34. Steinhilber D, Radmark O, Samuelsson B. Transforming growth factor β upregulates 5-lipoxygenase activity during myeloid cell maturation. Proc Natl Acad Sci U S A 1993; 90:5984-5988
35. Shim YM, Zhu Z, Zheng T, et al. Role of 5-lipoxygenase in IL-13-induced pulmonary inflammation and remodeling. J Immunol 2006; 177:1918-1924
36. Peebles RS Jr, Dworski R, Collins RD, et al. Cyclooxygenase inhibition increases interleukin 5 and interleukin 13 production and airway hyperresponsiveness in allergic mice. Am J Respir Crit Care Med 2000; 162:676-681
37. Endo T, Ogushi F, Kawano T, et al. Comparison of the regulations by Th2-type cytokines of the arachidonic-acid metabolic pathway in human alveolar macrophages and monocytes. Am J Respir Cell Mol Biol 1998; 19:300-307
38. Espinosa K, Bosse Y, Stankova J, et al. CysLT1 receptor upregulation by TGF-beta and IL-13 is associated with bronchial smooth muscle cell proliferation in response to LTD4. J Allergy Clin Immunol 2003; 111:1032-1040
39. Balbir-Gurman A, Braun-Moscovici Y, Livshitz V, et al. Antioxidant status after iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis. Clin Rheumatol 2007; 26:1517-1521
40. Allan EH, Martin TJ, Prostaglandin E2 regulates production of plasminogen activator isoenzymes, urokinase receptor, and plasminogen activator inhibitor-1 in primary cultures of rat calvarial osteoblasts. J Cell Physiol 1995; 165:521-529
41. Liu X, Ostrom RS, Insel PA. cAMP-elevating agents and adenylyl cyclase overexpression promote an antifibrotic phenotype in pulmonary fibroblasts. Am J Physiol Cell Physiol 2004; 286:C1089-C1099
42. Kowal-Bielecka O, Distler O, Kowal K, et al. Elevated levels of leukotriene B4 and leukotriene E4 in bronchoalveolar lavage fluid from patients with scleroderma lung disease. Arthritis Rheum 2003; 48:1639-1646
43. Selman M, Barquin N, Sansores R, et al. Increased levels of leukotriene C4 in bronchoalveolar lavage from patients with pigeon breeder's disease. Arch Invest Med (Mex) 1988; 19:127-131
44. Garcia JG, Griffith DE, Cohen AB, et al. Alveolar macrophages from patients with asbestos exposure release increased levels of leukotriene B4. Am Rev Respir Dis 1989; 139:1494-1501
45. Henderson WR Jr, Chiang GK, Tien YT, et al. Reversal of allergen-induced airway remodeling by CysLT1 receptor blockade. Am J Respir Crit Care Med 2006; 173:718-728
46. Kelly MM, Chakir J, Vethanayagam D, et al. Montelukast treatment attenuates the increase in myofibroblasts following low-dose allergen challenge. Chest 2006; 130:741-753
47. Pierzchalska M, Szabo Z, Sanak M, et al. Deficient prostaglandin E2 production by bronchial fibroblasts of asthmatic patients, with special reference to aspirin-induced asthma. J Allergy Clin Immunol 2003; 111:1041-1048
48. Tuder RM, Zaiman AL. Prostacyclin analogs as the brakes for pulmonary artery smooth muscle cell proliferation: is it sufficient to treat severe pulmonary hypertension? Am J Respir Cell Mol Biol 2002; 26:171-174
49. Phan SH, Kunkel SL. Inhibition of bleomycin-induced pulmonary fibrosis by nordihydroguaiaretic acid: the role of alveolar macrophage activation and mediator production. Am J Pathol 1986; 124:343-352
50. Izumo T, Kondo M, Nagai A. Cysteinyl-leukotriene 1 receptor antagonist attenuates bleomycin-induced pulmonary fibrosis in mice. Life Sci 2007; 80:1882-1886
51. Gauvreau GM, Watson RM, O'Byrne PM. Protective effects of inhaled PGE2 on allergen-induced airway responses and airway inflammation. Am J Respir Crit Care Med 1999; 159:31-36
52. Huang SK, Wettlaufer SH, Hogaboam CM, et al. Variable prostaglandin E2 resistance in fibroblasts from patients with usual interstitial pneumonia. Am J Respir Crit Care Med 2008; 177:66-74
53. Krowka MJ, Ahmad S, de Andrade JA, et al. A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of iloprost inhalation in adults with abnormal pulmonary arterial pressure and exercise limitation associated with idiopathic pulmonary fibrosis [abstract]. Chest 2007; 132:633a
54. Kujubu DA, Herschman HR. Dexamethasone inhibits mitogen induction of the TIS10 prostaglandin synthase/cyclooxygenase gene. J Biol Chem 1992; 267:7991-7994
55. Molina-Molina M, Serrano-Mollar A, Bulbena O, et al. Losartan attenuates bleomycin induced lung fibrosis by increasing prostaglandin E2 synthesis. Thorax 2006; 61:604-610
56. Phillips PG, Long L, Wilkins MR, et al. cAMP phosphodiesterase inhibitors potentiate effects of prostacyclin analogs in hypoxic pulmonary vascular remodeling. Am J Physiol Lung Cell Mol Physiol 2005; 288:L103-L115